Moo Young Song

USPTO Granted Patents = 14 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 8.8

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Gyeonggi-do, KR (2022)
Suwon-Si, KR (2004 - 2023)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12240913 - Anti-HER2/anti-4-1BB bispecific antibody and use thereof (2025-03-04),

2. 12168690 - Anti-EGFR/anti-4-1BB bispecific antibody (2024-12-17),

3. 11560416 - Method for producing dual function proteins and its derivatives (2023-01-24),

4. 11505603 - Anti-TIGIT antibodies and uses thereof (2022-11-22),

5. 11479596 - Fusion protein comprising thyrotropin receptor variants and use thereof (2022-10-25),

6. 11179440 - Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis (2021-11-23),

7. 7645450 - Humanized antibody specific for tumor necrosis factor-alpha (2010-01-12),

8. 7435414 - Humanized antibody against S-surface antigen of hepatitis B virus (2008-10-14),

9. 7196177 - Antibody variable region of a monoclonal antibody against human tumor necrosis factor alpha and a gene encoding the same (2007-03-27),

10. 7112664 - Variable region of the monoclonal antibody against the HBV S-surface antigen and a gene encoding the same (2006-09-26),

11. 7109320 - Nucleic acid molecules encoding human tumor necrosis factor α-specific antibodies (2006-09-19),

12. 6939956 - Variable region of the monoclonal antibody against HBV S-surface antigen and a gene encoding the same (2005-09-06),

13. 6924368 - Variable region of the monoclonal antibody against the HBV S-surface antigen and a gene encoding the same (2005-08-02),

14. 6680053 - Variable region of the monoclonal antibody against the HBV S-surface antigen and a gene encoding the same (2004-01-20),

Title: Innovator Moo Young Song: Pioneering Bispecific Antibodies for Cancer Treatment

Introduction: Moo Young Song, an esteemed inventor based in Suwon-si, South Korea, has made significant contributions to the field of biotechnology. With 14 patents to his name, his work primarily focuses on bispecific antibodies that play a crucial role in the treatment and prevention of cancer.

Latest Patents: Among his latest innovations are two notable patents. The first is for an "Anti-HER2/anti-4-1BB bispecific antibody and use thereof." This patent provides a composition and method aimed at treating and preventing cancer by utilizing a bispecific antibody targeting both HER2 and 4-1BB. The second patent features the "Anti-EGFR/anti-4-1BB bispecific antibody," which outlines a similar approach in addressing cancer through co-targeting the EGFR protein along with 4-1BB, enhancing therapeutic strategies for effective treatment.

Career Highlights: Moo Young Song has built a robust career in the pharmaceutical sector, notably working with leading companies such as Yuhan Corporation and Abl Bio Inc. His experience in these organizations has allowed him to push the boundaries of cancer treatment research and development.

Collaborations: Throughout his career, Moo Young Song has collaborated with several talented professionals, including In Young Ko and Tae Hyoung Yoo. Their collective expertise has fostered a productive environment for innovation and advancement in biopharmaceutical research.

Conclusion: Moo Young Song stands as a prominent figure in the realm of biotechnology, driven by his dedication to developing groundbreaking therapies for cancer. His innovative bispecific antibodies reflect his commitment to addressing critical challenges in cancer treatment, paving the way for new possibilities in medical advancements.

This text is generated by artificial intelligence and may not be accurate.